Yes, Gilenya (fingolimod) is a prescription medicine and was approved by regulators in the UK to treat highly active relapsing remitting multiple sclerosis in patients unresponsive to an interferon injection. The first oral treatment for multiple sclerosis was made available in the UK in 2011 following the launch of Novartis' Gilenya on the market, offering patients another medication option against the disease. According to Multiple Sclerosis Society , you can be prescribed Gildenya if you have the same or an increased number of relapses despite treatment. Gilenya (fingolimod) is approved in the US. In 2020, the FDA approved 3 new generic versions of Gilenya. Gilenya was first approved in 2010 by the FDA.